Big Pharma to seek only selected generics opportunities, IMS predicts
This article was originally published in Scrip
IMS Health made two significant predictions, among others, at the 13th annual International Generic Pharmaceutical Alliance (IGPA) conference in Mumbai. One was that Big Pharma is unlikely to emerge as a 'long-list' generics player, which appeared to be something that many in the audience anticipated and accepted.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
Pharmaceutical manufacturing in India is facing some early stress amid the new 21-day lock-down but both the industry and government machinery are actively engaged and working together to ensure that disruptions are minimized in the ‘pharmacy of the world.’
India has prohibited exports of hydroxychloroquine, though with concessions in specific instances, days after a national task force recommended the drug for the prophylaxis of SARS-CoV-2 infections. Home market supplies of the drug also appear strained for now.